2,891 trials (keyword fallback)
Hypertension, Pulmonary · Altitude Sickness
Primary: Mean Pulmonary Artery Pressure — 16.8667; 15.6545; 16.3800; 16.6833 mm Hg
Pain
Primary: Pain Management Used During Newborn Screening Blood Test — 30; 33 Participants
Pulmonary Arterial Hypertension
Primary: Safety of Low-dose FK-506 in PAH — 8; 18; 9; 22 number of AEs
Pulmonary Arterial Hypertension
Primary: 6-minute-walk Distance (6MWD) — 330.0; 328.6 meters — p=0.7883
Pulmonary Hypertension, Familial Persistent, of the Newborn
Primary: Time on Inhaled Nitric Oxide (iNO) Treatment After Initiation of Intravenous (IV) Study Drug For Participants Without Treatment Failure — 4.1; 4.1 days — p=0.9850
Congenital Diaphragmatic Hernia · Persistent Pulmonary Hypertension of the Newborn · Hypoxemic Respiratory Failure
Primary: Oxygenation Response — 4.2; 2.6 Change in Oxygenation Index
Obstructive Sleep Apnea · Resistant Hypertension · Hyperaldosteronism
Primary: Severity of Obstructive Sleep Apnea — -18.3; 7.0 events/hour
Chronic Thromboembolic Pulmonary Hypertension
Primary: Concentration of Matrix Metalloproteinase 2 and 9 Enzymes — 89289.89; 86548.72; 205707.83; 152911.57 ng/ml — p=<0.05
Congestive Heart Failure · Heart Failure, Left-Sided · Left-Sided Heart Failure
Primary: Change in 20 Watt Exercise Pulmonary Vascular Resistance (PVR) — -0.6; 0.1 wood units — p=0.003
Pulmonary Arterial Hypertension
Primary: Number of Participants With Side Effects and/or Adverse Events — 0 participants
Lung Neoplasms
Primary: Discharge 2weeks Exercise Capacity — 408.61; 311.94 meter(M) — p=<0.05
Pulmonary Hypertension
Primary: Cardiac Glucose Uptake in FDG-PET (Fluorodeoxyglucose-Positron Emission Tomography) — 1.0; 0.6; 0.9; 0.8 standardized uptake value (SUV) — p=0.04
Ventricular Tachycardia · Atrial Fibrillation
Primary: Amount of Treated Subjects With Freedom of Symptomatic Post-procedural AF or Flutter at 12 and 15 Months Post Procedure and Less Than 1 Min/Day of AF or Flutter on…
Pulmonary Arterial Hypertension
Primary: Treatment-emergent Adverse Events — 148; 139; 126 adverse events
Pulmonary Arterial Hypertension
Primary: Change From Baseline to End of Study (EOS) in Height for Age. — -0.8; 0.32; -0.64; -0.74 Z-score